SERDs Move Beyond Estrogen Blockade in ER-Positive Breast Cancer
Selective estrogen receptor degraders have moved from a narrow endocrine niche into a broader strategy for controlling ER-positive breast cancer, especially disease driven by ESR1 mutations. The review places that shift in direct clinical context: most breast cancers are estrogen receptor α positive, and the hormone signaling axis remains a dominant growth engine across early and metastatic disease. When the receptor stays active despite estrogen withdrawal, standard endocrine approaches lose force, and the tumor finds ways to keep transcribing survival and proliferation programs.
A central point runs through the review. ERα is no longer viewed only as a hormonal switch to be turned off; it is also a molecular node that can be reprogrammed, degraded, and used to reshape the tumor immune environment.
Why ESR1 Mutations Change the Therapeutic Equation
Activating hotspot mutations in ESR1 are especially important in metastatic ER-positive disease. The review identifies the two most prevalent alterations as Y537S and D538G, both of which stabilize a constitutively active receptor. In practical terms, the receptor behaves as if estrogen is still present, even when the ligand is absent or markedly suppressed. That biology explains why endocrine resistance so often emerges after prolonged treatment exposure.
These mutations do more than preserve signaling. They intensify oncogenic behavior by recruiting transcriptional coactivators, increasing histone acetylation, and opening chromatin in ways that favor metastasis-associated gene expression. The result is a tumor cell that is not only harder to suppress, but also more invasive and better equipped for dissemination. Certain mutant tumors also show reduced ligand-binding affinity, which weakens the activity of tamoxifen and raises the dose needed for effective suppression with other endocrine therapies.
Resistance is therefore both structural and functional. A receptor that is locked into an active conformation is difficult to silence with drugs designed for the wild-type protein.
Fulvestrant Set the Standard, but Its Limits Are Now Clear
Fulvestrant established the SERD class by directly antagonizing ERα and driving receptor degradation. It remains an essential second- or later-line therapy in advanced disease. The review notes, however, that its pharmacology comes with built-in liabilities: intramuscular administration, poor solubility, and limited oral bioavailability. Those drawbacks matter in metastatic breast cancer, where treatment often needs to be continuous, tolerable, and systemically effective across multiple sites.
Clinical performance has also exposed the ceiling of this first-generation approach. In metastatic cohorts, the review cites short progression-free survival with fulvestrant monotherapy, including especially limited activity in tumors carrying Y537S. Even where fulvestrant retains antitumor effects, those responses are often brief. Injection-site reactions, gastrointestinal adverse events, and arthralgia further constrain long-term use.
The drug is active, but the receptor biology it faces has become more demanding.
Oral SERDs Extend the Class Into New Pharmacologic Territory
The emergence of oral SERDs reflects an attempt to solve several problems at once. Oral dosing improves convenience and may broaden exposure across metastatic compartments. Better solubility also matters because the drug has to reach resistant lesions, not simply circulate in plasma.
Elacestrant is the first oral SERD approved for ER+/HER2– advanced breast cancer. Its structural behavior is unusual enough to create a distinct binding pose and a different set of coregulator interactions compared with older agents. The review links that chemistry to a neomorphic transcriptional program, one that may preserve antiproliferative activity even in settings shaped by CDK4/6 inhibitor resistance. In the EMERALD phase III trial, elacestrant improved progression-free survival compared with standard endocrine therapy, with the clearest benefit in patients whose tumors carried detectable ESR1 mutations. Among patients with D538G- or Y537S/N-mutated tumors who had already received prolonged endocrine therapy and a CDK4/6 inhibitor, the median progression-free survival was 8.6 months with elacestrant versus 1.9 months with standard therapy.
That gap is clinically meaningful. It marks a setting where a drug designed for receptor degradation and altered receptor conformation can still extract benefit after multiple prior lines of endocrine pressure.
The Immune Microenvironment Is Now Part of the SERD Story
The most interesting shift in the review is not limited to receptor pharmacology. SERDs appear to influence the breast cancer immune microenvironment as well.
This matters because endocrine therapy has often been discussed as if it acted only inside tumor cells. The new evidence suggests a wider field of action. By altering estrogen receptor signaling, SERDs may change the cytokine milieu, antigen presentation, and the composition or behavior of immune cells within the tumor bed. In other words, suppressing ERα may do more than slow tumor cell division; it may also loosen immune evasion programs that help malignant cells remain hidden or poorly immunogenic.
That concept is biologically plausible. Estrogen signaling can shape transcriptional programs that affect immune trafficking and local suppression. When a SERD dismantles the receptor and changes coregulator assembly, it may also alter the signals that determine whether the tumor microenvironment stays permissive or becomes less hospitable. The review treats this as an active area of investigation rather than a settled clinical endpoint, but the mechanistic direction is clear: endocrine therapy and antitumor immunity are not separate worlds.
Brain Penetration, Bone Effects, and the Next Questions for Practice
The review also points to tissue-specific considerations that may influence future prescribing. Elacestrant crosses the blood-brain barrier in healthy postmenopausal women, a property that could matter in breast cancer with central nervous system involvement. It also shows weak endometrial stimulation in uterine wet weight studies, suggesting that some residual tissue-selective estrogen receptor pharmacology may remain. The potential bone-sparing effect of preserving at least some estrogen receptor activity in selected tissues is another clinically relevant possibility.
These features complicate the old idea that every useful SERD must behave as a uniform global antiestrogen. In practice, a drug that is potent in tumor tissue yet tolerable in normal tissue may be more valuable than one that simply erases all estrogen receptor activity everywhere.
The next phase of SERD development will likely depend on how well these agents perform in biomarker-defined disease. ESR1 mutation status already separates patients likely to benefit from those less likely to respond. The immune effects raised in the review add another layer, especially if receptor degradation can be paired with strategies that amplify antitumor immunity in metastatic breast cancer. The field now needs clinical trials that connect mechanism with durable outcomes, not just receptor occupancy or short-term response curves. The unresolved issue is whether immune reprogramming from SERDs translates into longer disease control in the patients who need it most.